Pharmaceuticals

Rising Cardiovascular Disease Prevalence Fuels Growth in Peripheral Vasodilator Drugs Market Is Supporting Development Across The Peripheral Vasodilator Drugs Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Peripheral Vasodilator Drugs Market During The Forecast Period?

The peripheral vasodilator drugs market size has exhibited strong growth in recent years. It will grow from $6.61 billion in 2025 to $6.99 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. This historic growth is attributable to several key factors, including the rising prevalence of hypertension, an increased incidence of peripheral vascular diseases, the long-term clinical use of nitrates and calcium channel blockers, a growing cardiovascular disease burden, and expanding hospital-based cardiovascular treatment.

The peripheral vasodilator drugs market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $8.56 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this growth during the forecast period include an aging worldwide population, an increase in heart failure and angina cases, a rising need for outpatient cardiovascular care, wider acceptance of generic vasodilator medications, and enhanced diagnostic capabilities for peripheral circulation disorders. Key trends anticipated during the forecast period involve the expanding application of vasodilators in managing chronic hypertension, a greater inclination towards combination cardiovascular treatments, the increasing uptake of long-acting vasodilator formulations, a broadening scope of peripheral vasodilator utilization in heart failure treatment, and a move towards formulations with enhanced safety and tolerability.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16508&type=smp

Which Core Factors Are Supporting The Expansion Of The Peripheral Vasodilator Drugs Market?

The peripheral vasodilator drug market is anticipated to expand due to the rising occurrence of cardiovascular diseases. These disorders, known as CVDs, impact the heart and blood vessels, frequently resulting from atherosclerosis and manifesting as conditions such as heart attacks, strokes, hypertension, and heart failure. A primary reason for the increase in cardiovascular disease cases includes inactive lifestyles, poor dietary habits, an aging demographic, growing obesity rates, and associated health issues like diabetes and high blood pressure. In the context of cardiovascular diseases, peripheral vasodilators enhance blood circulation, lower blood pressure, lessen the heart’s effort, and relieve symptoms related to conditions such as peripheral arterial disease. For example, data from October 2024, provided by the Centers for Disease Control and Prevention (a US-based government agency), indicated that cardiovascular disease was responsible for 919,032 deaths in 2023, representing one in every three fatalities. Coronary heart disease continued to be the most common type of heart disease, and it was notable that roughly one in 6 deaths from cardiovascular diseases affected individuals under 65 years of age. Consequently, the rising incidence of cardiovascular diseases is fueling the expansion of the peripheral vasodilator drug market.

What Key Segment Areas Are Included In The Peripheral Vasodilator Drugs Market Assessment?

The peripheral vasodilator drugs market covered in this report is segmented –

1) By Drug Type: Calcium Channel Blockers, Direct-Acting Vasodilators, Alpha-Adrenergic Blockers, Potassium Channel Activators, Nitrates, Other Types

2) By Indication: Hypertension, Angina, Heart Failure, Other Indications

3) By Application: Hospital, Retail Pharmacies, Other Applications

Subsegments:

1) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

2) By Direct-Acting Vasodilators: Hydralazine, Minoxidil, Nitroprusside

3) By Alpha-Adrenergic Blockers: Prazosin, Doxazosin, Terazosin

4) By Potassium Channel Activators: Nicorandil, Diazoxide

5) By Nitrates: Nitroglycerin, Isosorbide Dinitrate, Isosorbide Mononitrate

6) By Other Types: Phosphodiesterase Inhibitors, Endothelin Receptor Antagonists

Which Trends Are Influencing The Direction Of The Peripheral Vasodilator Drugs Market?

Companies operating within the peripheral vasodilator drugs market are prioritizing drug development, particularly triple-drug combination therapies, to enhance treatment outcomes and expand their market presence in cardiovascular therapeutics. This triple-drug combination therapy is an antihypertensive fixed-dose combination (FDC) designed for patients who have not achieved adequate blood pressure control with dual-drug therapies or cannot tolerate diuretic-based combinations. For example, in August 2023, Ajanta Pharma Limited, an India-based pharmaceutical company specializing in cardiology, introduced Met XL AMT, a new triple-drug combination aimed at managing hypertension among Indian patients. This product is a fixed-dose combination (FDC) consisting of three antihypertensive agents: Telmisartan, Amlodipine, and Metoprolol. These agents collectively work to reduce blood pressure by relaxing blood vessels, which is a key characteristic of peripheral vasodilators. The drug holds specific approval from DCGI for managing uncontrolled hypertension alongside stable coronary artery disease, positioning it as the world’s first fixed-dose combination (FDC) of metoprolol succinate (extended-release) 50 mg, amlodipine 5 mg, and telmisartan 40 mg.

Who Are The Companies Shaping The Peripheral Vasodilator Drugs Market Landscape?

Major companies operating in the peripheral vasodilator drugs market are Pfizer Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company, Gilead Sciences Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Merck & Co, Viatris Inc., Teva Pharmaceutical Industries, Astellas Pharma, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Cipla Limited, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Ipca Laboratories, Alembic Pharmaceuticals

Access The Complete Peripheral Vasodilator Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

Which Region Is The Dominant Market In The Peripheral Vasodilator Drugs Market?

North America was the largest region in the peripheral vasodilator drugs market in 2025. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Peripheral Vasodilator Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=16508&type=smp

Browse Through More Reports Similar to the Global Peripheral Vasodilator Drugs Market 2026, By The Business Research Company

Peripheral Vasodilator Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

Vasodilators Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795